NASDAQ · Financial Statements

Regencell Bioscience Holdings Limited (RGC) Revenue, Earnings & Financial Statements

$4.55 NASDAQ: RGC Market Cap $2.26B

Data as of Nov 17, 2026 close · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)

Regencell Bioscience Holdings Limited most recently reported annual revenue of $0, a net loss of $12.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Regencell Bioscience Holdings Limited: net profit was positive in 0 of 8 reported years; the most recent year shows a net loss of $12.0M.

Income Statement — 8 Years (USD millions)

Metric20192020202120222023202420252026
Revenue$0$0$0$0$0$0$0$0
Operating Expenses$0$1.0M$1.0M$8.0M$6.0M$5.0M$4.0M$12.0M
Operating Profit$0−$1.0M−$1.0M−$8.0M−$6.0M−$5.0M−$4.0M−$12.0M
Other Income$0$0$0$0$0$0$0$0
Interest$0$0$0$0$0$0$0$0
Depreciation$0$0$0$1.0M$1.0M$1.0M$0$0
Profit Before Tax$0−$1.0M−$1.0M−$8.0M−$6.0M−$4.0M−$4.0M−$12.0M
Tax rate (%)0.1%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit$0−$1.0M−$1.0M−$7.0M−$6.0M−$4.0M−$4.0M−$12.0M
EPS$0.00$0.00$0.00−$0.01−$0.01−$0.01−$0.01−$0.02

Quarterly Results — Last 12 Quarters (USD millions)

2 duplicate period labels in the source data were collapsed.

MetricDec '20Jun '21Dec '21Jun '22Dec '22Jun '23Dec '23Jun '24Dec '24Jun '25Dec '25Jun '26
Revenue$0$0$0−$2.3B$0$0$0$0$0$0$0$0
Operating Expenses$0$0$4.0M−$2.3B$3.0M$3.0M$0$0$2.0M$2.0M$5.0M$6.0M
Operating Profit$0$0−$4.0M−$4.0M−$3.0M−$3.0M$0$0−$2.0M−$2.0M−$5.0M−$6.0M
Operating Margin———0.2%————————
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$0−$1.0M−$4.0M−$4.0M−$3.0M−$3.0M$0$0−$2.0M−$2.0M−$5.0M−$6.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%5.5%0.0%0.0%0.0%0.0%0.0%
Net Profit$0$0−$4.0M−$4.0M−$3.0M−$3.0M$0$0−$2.0M−$2.0M−$5.0M−$6.0M
EPS$0.00$0.00−$0.01−$0.01−$0.01−$0.01$0.00$0.00$0.00$0.00−$0.01−$0.01

Over the 8 years reported for Regencell Bioscience Holdings Limited, borrowings decreased from $2.0M in 2019 to $0 in 2026, cash stood at $14.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.00 times.

Balance Sheet — 8 Years (USD millions)

Metric20192020202120222023202420252026
Total Assets$0$1.0M$0$18.0M$13.0M$8.0M$6.0M$15.0M
Current Assets$0$0$0$16.0M$12.0M$8.0M$5.0M$14.0M
Cash$0$0$0$6.0M$2.0M$3.0M$2.0M$14.0M
Inventory$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0
Fixed Assets$0$0$0$1.0M$1.0M$0$1.0M$0
Capital Work in Progress$0$0$0$0$0$0$0$0
Investments$0$0$0$10.0M$10.0M$5.0M$2.0M$0
Other Assets$0$0$0$0$0$0$0$0
Total Liabilities$2.0M$3.0M$4.0M$1.0M$1.0M$0$1.0M$1.0M
Current Liabilities$2.0M$3.0M$4.0M$1.0M$1.0M$0$1.0M$1.0M
Borrowings$2.0M$3.0M$4.0M$1.0M$0$0$1.0M$0
Other Liabilities$0$0$1.0M$0$0$0$0$1.0M
Equity$0$0$0$0$0$0$0$0
Reserves−$2.0M−$3.0M−$4.0M$17.0M$12.0M$8.0M$5.0M$13.0M

For Regencell Bioscience Holdings Limited, operating cash flow was positive in 0 of 8 reported years; free cash flow in the latest year was negative at $8.0M; free cash flow was positive in 0 of 8 years; financing activities used $2.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 8 Years (USD millions)

Metric20192020202120222023202420252026
Operating Cash Flow$0−$1.0M−$1.0M−$5.0M−$5.0M−$4.0M−$3.0M−$8.0M
Investing Cash Flow$0$0$0−$12.0M$0$5.0M$3.0M$3.0M
Financing Cash Flow$0$1.0M$0$22.0M$0$0$0−$2.0M
Net Cash Flow$0$0$0$6.0M−$5.0M$1.0M−$1.0M$12.0M
Free Cash Flow$0−$1.0M−$1.0M−$6.0M−$5.0M−$4.0M−$3.0M−$8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio2.82
EV / EBITDA-287.68
FCF Yield-0.24%
Quick Ratio10.77
Interest Coverage—
Return 1Y-62.00%
Return 3Y1290.52%
Return 5Y717.74%

Regencell Bioscience Holdings Limited (RGC) financials — frequently asked questions

What is Regencell Bioscience Holdings Limited's annual revenue?

Regencell Bioscience Holdings Limited (RGC) reported annual revenue of $0 in its most recent fiscal year.

What is Regencell Bioscience Holdings Limited's net profit?

Regencell Bioscience Holdings Limited (RGC) reported a net loss of $12.0M in its most recent fiscal year.

What is RGC EV/EBITDA?

Regencell Bioscience Holdings Limited's enterprise value to EBITDA (EV/EBITDA) ratio is -287.68. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Drug Manufacturers - Specialty & Generic stocks

TEVA revenue $17.3BZTS revenue $9.5BVTRS revenue $14.3BELAN revenue $4.7BRDY revenue $353.5BALKS revenue $1.5BAMRX revenue $3.0BLNTH revenue $1.5BSUPN revenue $719.0MBHC revenue $10.3BAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
RGC Overview RGC Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.